𝔖 Bobbio Scriptorium

✦ LIBER ✦

265 ORAL BCIRG 006: Superior cardiac safety of adjuvant docetaxel (T), carboplatin (C) and trastuzumab (H) compared to doxorubicin (A) and cyclophosphamide (Cyc) followed by TH in patients with early stage breast cancer and altered HER2 gene

Book ID: 118622845
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 138 KB
Volume: 3
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(05)80563-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Docetaxel, carboplatin and trastuzumab (

Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiac toxicity confined to AC-TH: BCIRG 006 study

✍ J. Crown; Eiermann; N. Robert; T. Pienkowski; M. Martin; M. Pawlicki; A. Chan; M 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 142 KB

Cardiac safety analysis of the first sta

Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)

✍ C Geyer; J Bryant; E Romond; E Tan-Chiu; M Ewer; D Keefe; R Shannon; G Yothers; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 541 KB